Group One Trading’s Gain Therapeutics GANX Stock Holding History

Group One Trading’s Portfolio GANX Stock Details GANX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$7.73K	Sell	3,808 -2,596	-41%	-$4.79K	﹤0.01%	6554
2026 Q1	$12.4K	Sell	6,404 -47,755	-88%	-$104K	﹤0.01%	6243
2025 Q4	$174K	Buy	54,159 +37,384	+223%	+$99.8K	﹤0.01%	4502
2025 Q3	$29.7K	Buy	16,775 +10,374	+162%	+$17.5K	﹤0.01%	6379
2025 Q2	$11.5K	Buy	+6,401	New	+$11.8K	﹤0.01%	6628
2024 Q4	–	Sell	-1,401	Closed	-$2.81K	–	7489
2024 Q3	$2.49K	Sell	1,401 -6,000	-81%	-$7.54K	﹤0.01%	6090
2024 Q2	$9.47K	Buy	7,401 +5,400	+270%	+$14K	﹤0.01%	5673
2024 Q1	$7.54K	Sell	2,001 -1,936	-49%	-$8.03K	﹤0.01%	6009
2023 Q4	$12.9K	Buy	3,937 +2,000	+103%	+$5.56K	﹤0.01%	6045
2023 Q3	$6.26K	Buy	1,937 +1,090	+129%	+$4.13K	﹤0.01%	6580
2023 Q2	$3.79K	Buy	+847	New	+$4.13K	﹤0.01%	6836

Other funds holding GANX

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

PCM

Potomac Capital Management New York $147M AUM

GCP

GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return

Cambridge Investment Research Advisors Fairfield, Iowa $44.6B AUM 28.94% 1-Year Est. Return

DCM

DME Capital Management New York $3.91B AUM 36.1% 1-Year Est. Return

Jones Financial Companies Des Peres, Missouri $250B AUM 21.32% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Group One Trading's GANX Position: Q2 2026 in Review

Group One Trading reduced its Gain Therapeutics (GANX) stake by 41% in Q2 2026, selling an estimated $4.79K and leaving 3,808 shares worth $7.73K. The position accounts for ﹤0.01% of the portfolio, ranked #6554.

Group One Trading first reported a position in GANX in Q2 2023 and has held it in 11 quarters since. The position peaked at $174K in Q4 2025. 50 funds tracked by Wall St. Rank hold GANX as of Q2 2026.

Group One Trading held 3,808 shares of Gain Therapeutics worth $7.73K as of Q2 2026.
Group One Trading sold 2,596 Gain Therapeutics shares in Q2 2026, an estimated $4.79K.
Gain Therapeutics made up ﹤0.01% of Group One Trading's portfolio in Q2 2026, its #6554 holding.
Group One Trading first reported a position in Gain Therapeutics in Q2 2023 and has held it in 11 quarters since.
Group One Trading's Gain Therapeutics position peaked at $174K in Q4 2025.
50 funds tracked by Wall St. Rank held Gain Therapeutics as of Q2 2026.

Based on Group One Trading's 13F filing for Q2 2026, filed 14 Aug 2026.